Status:

COMPLETED

Safety and Efficacy of Emixustat in Stargardt Disease

Lead Sponsor:

Kubota Vision Inc.

Collaborating Sponsors:

Food and Drug Administration (FDA)

Conditions:

Stargardt Disease

Eligibility:

All Genders

16+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA O...

Detailed Description

Stargardt disease is a rare, inherited degenerative disease of the retina affecting approximately 1 in 8000 to 10 000 people and is the most common type of hereditary macular dystrophy. There are no a...

Eligibility Criteria

Inclusion

  • A clinical diagnosis of macular atrophy secondary to Stargardt disease (STGD)
  • Macular atrophy measured to fall within a defined size range
  • Two mutations of the ABCA4 gene. If only one mutation, a typical STGD appearance of the retina.
  • Visual acuity in the study eye of at least 20/320

Exclusion

  • Macular atrophy secondary to a disease other than STGD
  • Mutations of genes, other than ABCA4, that are associated with retinal degeneration
  • Surgery in the study eye in the past 3 months
  • Prior participation in a gene therapy or stem cell clinical trial for STGD
  • Recent participation in a clinical trial for STGD evaluating a complement inhibitor or vitamin A derivative
  • Use of certain medications in the past 4 weeks that might interfere with emixustat
  • An abnormal electrocardiogram (ECG)
  • Certain abnormalities on laboratory blood testing
  • Female subjects who are pregnant or nursing

Key Trial Info

Start Date :

January 7 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 23 2022

Estimated Enrollment :

194 Patients enrolled

Trial Details

Trial ID

NCT03772665

Start Date

January 7 2019

End Date

June 23 2022

Last Update

May 30 2024

Active Locations (29)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (29 locations)

1

Retina-Vitreous Associates Medical Group

Beverly Hills, California, United States, 90211

2

UCSF Dept. of Ophthalmology

San Francisco, California, United States, 94143-0730

3

Emory University

Atlanta, Georgia, United States, 30322

4

The Wilmer Eye Institute Johns Hopkins University

Baltimore, Maryland, United States, 21287